As part of a pilot study designed to advance personalized treatment for children and teens battling recurrent cancer, the Hyundai Cancer Institute at CHOC Children’s, Orange, Calif, is utilizing Illumina’s RapidTrack Whole Genome Sequencing (RapidTrack WGS) service for cancer samples. RapidTrack WGS will enable the study to gather whole genome sequencing data in high depth within 14 days. The data generated by Illumina will then by analyzed by the Translational Genomics Research Institute (TGen), another partner of the Hyundai Cancer Institute, to provide efficient customized interpretation to the CHOC physicians and researchers, who are part of the hospital’s Molecular Profiling Tumor Board. Twelve patients are currently enrolled in the study, which underscores the value of whole genomics sequencing as a diagnostic tool to help physicians decide the best course of treatment as quickly as is possible.
